We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Scientists from SRI International and Collaborations Pharmaceuticals in the US have identified a potential new inhibitor, tilorone dihydrochloride, for infection by Ebola virus.
Despite a frantic effort to rush Ebola vaccines through testing during a deadly epidemic, Merck & Co. will fall short of its goal to file its candidate for FDA approval this year, the company confirmed Tuesday.